HomeMarket NewsSmall Caps Insider Trades Shaping penny Stocks Market Insiders Making Big Bets on Penny Stocks:...

Insider Trades Shaping penny Stocks Market Insiders Making Big Bets on Penny Stocks: A Sign of Growth Or Just a Gamble?

Actionable Trade Ideas

always free


The Dow Jones index closed higher by over 150 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.

OPKO Health

  • The Trade: OPKO Health, Inc. OPK Chief Innovation Officer Gary Nabel acquired a total of 216,184 shares an average price of $0.93. To acquire these shares, it cost around $200,427.
  • What’s Happening: OPKO Health recently priced private offering of $200 million convertible senior notes due 2029.
  • What OPKO Health Does: OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs.


  • The Trade: LivePerson, Inc. LPSN 10% owner Alexander Slusky acquired a total of 1,805,569 shares at at an average price of $3.49. To acquire these shares, it cost around $6.29 million.
  • What’s Happening: LivePerson named John Sabino as CEO.
  • What LivePerson Does: LivePerson Inc offers cloud-based platform solutions. It enables businesses and consumers to connect through conversational interfaces, such as in-app and mobile messaging, while leveraging bots and Artificial Intelligence (AI) to increase efficiency.

Check This Out: Don’t Miss These 3 Energy Stocks With Over 3% Dividend Yields From Wall Street’s Most Accurate Analysts

Cell MedX

  • The Trade: Cell MedX Corp. CMXC CEO David Jeffs acquired a total of 88,959,726 shares at an average price of $0.01. The insider spent around $622,718 to buy those shares.
  • What’s Happening: Cell MedX recently entered into agreements to settle debt in the aggregate amount of $1,622,693 for shares at a price of $0.007 per share for an aggregate of 231,813,310 shares of common stock.
  • What Cell MedX Does: Cell MedX Corp is an early stage development company focused on the discovery, development and, commercialization of therapeutic products for patients with diseases such as diabetes, by developing technologies to help manage the illness and related complications.

Don’t forget to check out our premarket coverage here

Is this a smart move, or are these insiders taking reckless risks? How will these transactions impact the stock market?

While the broader market enjoys an upswing, these insiders are popping the champagne over their stock dealings. But is it a cause for champagne toasts or concern?

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.